Regarding the correlation between EFNB1 and drug sensitivity, we found that HCC patients with high EFNB1 expression exhibited a better drug response to doxorubicin (p = 0.0001), gemcitabine (p = 1.91e-8), and mitomycin C (p = 1e-05) than those with low EFNB1 expression, while the opposite results were discovered for cisplatin (p = 0.049) and sorafenib (p = 1e-06) (Figures 10M–R). Here, EFNB1 is linked to hepatocellular carcinoma.